Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis

Obeticholic acid (OCA) is approved for the treatment of patients with primary biliary cholangitis (PBC) who are partial responders or intolerant to ursodeoxycholic acid. Reports of serious liver injury have raised concerns about its safety in cirrhosis. We investigated the effects of treatment with...

Descripción completa

Detalles Bibliográficos
Autores principales: John, Binu V., Schwartz, Kaley, Levy, Cynthia, Dahman, Bassam, Deng, Yangyang, Martin, Paul, Taddei, Tamar H., Kaplan, David E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369937/
https://www.ncbi.nlm.nih.gov/pubmed/34430786
http://dx.doi.org/10.1002/hep4.1720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369937/
https://www.ncbi.nlm.nih.gov/pubmed/34430786
http://dx.doi.org/10.1002/hep4.1720

Ejemplares similares